Sporadic and infectious human prion diseases. Cold Spring Harbor perspectives in medicine, vol.7, 2017. ,
Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease, Brain J Neurol, vol.129, pp.2278-2287, 2006. ,
The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature, Neurology, vol.37, issue.6, pp.895-904, 1987. ,
Human prion diseases in the United States, PLoS One, vol.5, issue.1, p.8521, 2010. ,
Differential diagnosis of 201 possible CreutzfeldtJakob disease patients, J Neurol, vol.251, issue.3, pp.298-304, 2004. ,
Differential diagnosis of Jakob-Creutzfeldt disease, Arch Neurol, vol.69, issue.12, pp.1578-1582, 2012. ,
Rapidly progressive Alzheimer's disease and elevated 14-3-3 proteins in cerebrospinal fluid, Age Ageing, vol.37, issue.4, pp.467-469, 2008. ,
Rapidly progressive Alzheimer's disease mimicking Creutzfeldt-Jakob disease, J Neurol, vol.251, issue.8, pp.1020-1022, 2004. ,
, Mol Neurobiol
Cerebrospinal fluid biomarker supported diagnosis of CreutzfeldtJakob disease and rapid dementias: a longitudinal multicentre study over 10 years, Brain J Neurol, vol.135, pp.3051-3061, 2012. ,
The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies, N Engl J Med, vol.335, issue.13, pp.924-930, 1996. ,
Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease, Ann Neurol, vol.43, issue.1, pp.32-40, 1998. ,
Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid, Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia, vol.7, issue.3, pp.203-208, 2000. ,
, WHO manual for surveillance of human transmissible spongiform encephalopathies, including variant CreutzfeldtJakob disease, World Health Organization, 2003.
Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease, Neurology, vol.63, issue.3, pp.443-449, 2004. ,
Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease, Brain J Neurol, vol.132, pp.2659-2668, 2009. ,
protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease, Neurosci Lett, vol.320, issue.1-2, pp.69-72, 2002. ,
Neuroprotective function of 14-3-3 proteins in neurodegeneration, Biomed Res Int, p.564534, 2013. ,
protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt-Jakob disease patients in the progressive and terminal stages, Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia, vol.13, issue.6, pp.661-665, 2006. ,
Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, J Neurochem, vol.73, issue.6, pp.2485-2490, 1999. ,
Establishment of a standard 14-33 protein assay of cerebrospinal fluid as a diagnostic tool for Creutzfeldt-Jakob disease, Laboratory investigation; a journal of technical methods and pathology, vol.90, issue.11, pp.1637-1644, 2010. ,
Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease, J Neurol Neurosurg Psychiatry, vol.70, issue.6, pp.744-748, 2001. ,
Precision and variance components in quantitative gel electrophoresis, Electrophoresis, vol.26, issue.12, pp.2470-2475, 2005. ,
Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic, Mol Neurobiol, vol.53, issue.4, pp.2189-2199, 2016. ,
The French surveillance network of Creutzfeldt-Jakob disease. Epidemiological data in France and worldwide. Transfusion clinique et biologique: journal de la Societe francaise de transfusion sanguine, vol.20, pp.395-397, 2013. ,
Increased detection of 14-3-3 protein in cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease during the disease course, Eur Neurol, vol.48, issue.4, pp.218-221, 2002. ,
Interference testing, The Clinical biochemist Reviews, vol.29, issue.1, pp.43-48, 2008. ,
Reproducibility crisis: blame it on the antibodies, Nature, vol.521, issue.7552, pp.274-276, 2015. ,
Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease, Ann Neurol, vol.70, issue.3, pp.437-444, 2011. ,
Rapidly progressive dementia, Ann Neurol, vol.64, issue.1, pp.97-108, 2008. ,
Levels of immunoreactive aldolase C, creatine kinase-BB, neuronal and non-neuronal enolase, and 143-3 protein in circulating human blood cells, Clinica chimica acta; international journal of clinical chemistry, vol.136, issue.2-3, pp.219-228, 1984. ,
Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology, Neurology, vol.79, issue.14, pp.1499-1506, 2012. ,
[1]-isoform detection distinguishes sporadic Creutzfeldt-Jakob disease from other dementias, J Neurol Neurosurg Psychiatry, vol.76, issue.1, pp.100-102, 2005. ,
High sensitivity of an ELISA kit for detection of the gamma-isoform of 14-3-3 proteins: usefulness in laboratory diagnosis of human prion disease, BMC Neurol, vol.11, p.120, 2011. ,
Sporadic CreutzfeldtJakob disease diagnostic accuracy is improved by a new CSF ELISA 14-3-3gamma assay, Neuroscience, vol.322, pp.398-407, 2016. ,
The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prionunrelated neurological diseases is expressed constitutively in neurons and glial cells in culture, Eur Neurol, vol.41, issue.4, pp.216-225, 1999. ,
An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients, Ann Neurol, vol.48, issue.3, pp.395-398, 2000. ,
protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, Dement Geriatr Cogn Disord, vol.10, issue.1, pp.40-46, 1999. ,
Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias, Mol Psychiatry, vol.8, issue.3, pp.343-347, 2003. ,
Increased alpha-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease, J Neurol, vol.261, issue.6, pp.1203-1209, 2014. ,
, , 2002.
Validation of alpha-Synuclein as a CSF biomarker for sporadic Creutzfeldt-Jakob disease, Mol Neurobiol, 2017. ,
Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease, JAMA neurology, vol.72, issue.3, pp.267-275, 2015. ,
Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease, Ann Neurol, vol.72, issue.2, pp.278-285, 2012. ,
Evaluation of automated Wes system as an analytical and characterization tool to support monoclonal antibody drug product development, J Pharm Biomed Anal, 2016. ,
High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer, BMC Cancer, vol.16, issue.1, p.683, 2016. ,
Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands, Electrophoresis, vol.36, issue.2, pp.355-362, 2015. ,
Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine, Int J Mol Sci, vol.17, issue.2, 2016. ,
, 2% Patient, vol.4, issue.28, p.6
, Development of an automated capillary nano-immunoassay-Simple Western assay-to quantify total TDP43 protein
Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management, CNS Drugs, vol.24, issue.5, pp.375-98, 2010. ,
Clinical review. Frontotemporal dementia, BMJ, vol.347, 2013. ,
Frontotemporal dementia, Lancet Neurol, vol.4, issue.11, pp.70223-70227, 2005. ,
Primary progressive aphasia: clinicopathological correlations, Nat Rev Neurol, vol.6, issue.2, pp.88-97, 2010. ,
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine, Acta Neuropathol, vol.129, issue.4, pp.469-91, 2015. ,
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, vol.134, pp.2456-77, 2011. ,
Classification of primary progressive aphasia and its variants, Neurology, vol.76, issue.11, pp.1006-1020, 2011. ,
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Science, vol.314, issue.5796, pp.130-133, 2006. ,
Pathomechanisms of TDP-43 in neurodegeneration, J Neurochem, 2018. ,
TDP-43 post-translational modifications in health and disease, Expert Opin Ther Targets, vol.22, issue.3, pp.279-93, 2018. ,
On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia, Prog Neurobiol, vol.95, issue.4, pp.649-62, 2011. ,
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on AgingAlzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, vol.7, issue.3, pp.263-272, 2011. ,
Developing novel blood-based biomarkers for Alzheimer's disease, Alzheimers Dement, vol.10, issue.1, pp.109-123, 2014. ,
Frontotemporal lobar degeneration: current perspectives, Neuropsychiatr Dis Treat, vol.10, pp.297-310, 2014. ,
Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis, Acta Neuropathol, vol.117, issue.1, pp.55-62, 2009. ,
Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration, Acta Neuropathol, vol.118, issue.5, pp.647-58, 2009. ,
Towards a TDP-43-based biomarker for ALS and FTLD, Mol Neurobiol, 2018. ,
Western blotting using capillary electrophoresis, Anal Chem, vol.83, issue.4, pp.1350-1355, 2011. ,
Microfluidic Western blotting, Proc Natl Acad Sci U S A, vol.109, issue.52, pp.21450-21455, 2012. ,
Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics, J Transl Med, vol.13, p.182, 2015. ,
Role of platelets in neurodegenerative diseases: a universal pathophysiology, Int J Neurosci, vol.123, issue.5, pp.287-99, 2013. ,
Development and validation of pedigree classification criteria for frontotemporal lobar degeneration, JAMA Neurol, vol.70, issue.11, pp.1411-1418, 2013. ,
A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories, J Med Genet, vol.51, issue.6, pp.419-443, 2014. ,
TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies, Acta Neuropathol Commun, vol.3, p.15, 2015. ,
, J Vis Exp, issue.127, 2017.
,
Performing and optimizing Western blots with an emphasis on chemiluminescent detection, Methods Enzymol, vol.463, issue.09, pp.63033-63033, 2009. ,
Detergent binding explains anomalous SDS-PAGE migration of membrane proteins, Proc Natl Acad Sci U S A, vol.106, issue.6, pp.1760-1765, 2009. ,
, R&D systems a biotechne brand. Human/Mouse/Rat TDP-43/ TARDBP Antibody-Monoclonal Mouse IgG2A Clone # 671834-Catalog Number: MAB7778
TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Arch Neurol, vol.65, issue.11, pp.1481-1488, 2008. ,
Protein quantification by chemiluminescent Western blotting: elimination of the antibody factor by dilution series and calibration curve, J Immunol Methods, vol.353, issue.1-2, pp.148-50, 2010. ,
Detection of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease patients using a new automated capillary Western assay, Mol Neurobiol, 2017. ,
CSF biomarker variability in the Alzheimer's Association quality control program, Alzheimers Dement, vol.9, issue.3, pp.251-61, 2013. ,
Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS, Exp Neurol, vol.262, pp.84-90, 2014. ,